Topical and oral tranilast for treatment of dry eye associated with chronic graft-versus-host disease

Topical and oral tranilast for treatment of dry eye associated with chronic graft-versus-host disease - Effect of tranilast for treatment of dry eye

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006763

Enrollment

Registered

2011-12-01

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye related to cGVHD

Interventions

Topical tranilast Oral tranilast

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnostic criteria Tear Dynamics Schirmer test &#8804; 5 mm Tear break up time &#8804; 5 sec Ocular surface condition Rose Bengal staining &#8805; 3 points Fluorescein staining &#8805; 3 points Newly onset of dry eye patients after hematopoietic stem cell transplantation

Exclusion criteria

Exclusion criteria: Contact lens wearer Infectious disease Other ocular disease

Design outcomes

Primary

Measure	Time frame
visual analog scale ocular surface vital staining tear break up time value of schirmer test value of nasal stimulation test	—

Secondary

Measure	Time frame
visual acuity functional visual acuity tear stability analysis system tear lipid interferometory	—

Countries

Japan

Contacts

Public ContactYoko Ogawa

Keio University School of Medicine Department of Ophthalmology

03-5363-3972

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026